Is Shanghai Xinxing Pharmaceutical Co., Ltd. a state-owned enterprise? How is the treatment?

Xinxing Medicine Shanghai Xinxing Medicine Co., Ltd. is a blood product manufacturer designated by the state. It is a high-tech export-oriented pharmaceutical group integrating pharmaceutical production, management, scientific research and development, and is relatively controlled by China Xinxing (Group) Corporation. The company is a key high-tech enterprise in the national torch plan, a high-tech enterprise in Shanghai, a third-class enterprise in science and technology industrialization in Shanghai, and an excellent industrial enterprise in Shanghai. The company has a postdoctoral research center, a GMP certificate issued by SFDA in China, a first-class blood product factory in Asia, a group of high-level R&D teams and a pharmaceutical sales network all over the country. The company's main products include eight series of products, including various specifications of human albumin, gamma globulin for intravenous injection (pH4), human prothrombin complex, rabies immunoglobulin and hepatitis B immunoglobulin. China Xinxing (Group) Corporation, an emerging group, is now a wholly-owned subsidiary of China General Technology (Group) Holding Co., Ltd., with construction real estate, arms trade and high-tech medicine as its three pillar industries. In 2009, Xinxing Group consolidated assets of 965.438+85 million yuan, owners' equity of 2.035 billion yuan, operating income of 9.687 billion yuan and profit of 285 million yuan, among which the accumulated operating income of construction real estate, import and export trade and blood products pharmaceutical enterprises was 8.035 billion yuan, accounting for 82.94% of the total income of the Group. Realized a profit of 265 million yuan, accounting for 92.92% of the Group's consolidated profit. Shanghai Xinxing Pharmaceutical Co., Ltd. was established in August 2000 with a registered capital of 654.38+64 million yuan and total assets of more than 400 million yuan. The company is mainly engaged in the production and sales of blood products and the wholesale business of other pharmaceutical products. With an investment of 654.38+0.7 billion yuan, it has passed GMP certification and has a first-class blood product production factory in Asia. At the same time, the pharmaceutical sales department with GSP certification is a high-tech, export-oriented pharmaceutical group integrating scientific research, production, trade and investment. The company is a national key high-tech enterprise. Since 1995, the company has been rated as one of the top 100 scientific and technological enterprises in Shanghai year after year, and since 1998, it has been recognized as a high-tech enterprise in Shanghai year after year. 1999, listed as one of the "top three" enterprises in Shanghai's science and technology industrialization (enterprise scale, product level and benefit of over 100 million yuan). Since 2000, it has been rated as one of the "Top 100" enterprises in the transformation of high-tech achievements in Shanghai. 200 1 was rated as an excellent industrial enterprise in Shanghai. Since 2002, it has been recognized as a national key high-tech enterprise by the Ministry of Science and Technology. At the end of 2003, the post-doctoral research mobile station was approved by the state. The company's leading products, such as human albumin, human immunoglobulin and human prothrombin complex, have been recognized as national key new products, Shanghai municipal new products and Shanghai high-tech achievements transformation projects, and have been included in the national torch plan and Shanghai torch plan. The newly developed products such as human fibrin glue and hepatitis B immunoglobulin have been recognized by the Ministry of Science and Technology as national scientific and technological innovation projects and Shanghai high-tech achievements transformation projects. Wang Zhihua, the chairman of the company, is the chief pharmacist. He has won the honors of the Third National Outstanding Young Entrepreneur, the National Outstanding Entrepreneur Nomination Award, the Second China Youth Science and Technology Entrepreneurship Award, and the 2002 Shanghai Science and Technology Entrepreneurship Leader. In 2003, he was specially invited as a member of the National Council of Entrepreneurs in China, and in 2004, he was appointed as the new executive director of the China Industrial and Commercial Council. Companies adhering to the "innovation, enterprising, honest, realistic" spirit of enterprise, keep pace with the times and make great efforts to govern. We are actively planning to go public, step into a new development stage of capital operation, become better, stronger and bigger, and create a better future together.